Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Financing Activities (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Cash from Financing Activities for 6 consecutive years, with $15000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 60.53% year-over-year to $15000.0, compared with a TTM value of $28000.0 through Sep 2025, down 99.91%, and an annual FY2024 reading of $622000.0, down 97.96% over the prior year.
  • Cash from Financing Activities was $15000.0 for Q3 2025 at Ovid Therapeutics, up from $13000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $30.0 million in Q4 2023 and bottomed at -$43599.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $1.9 million, with a median of $109549.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities crashed 139.93% in 2022, then soared 68984.61% in 2023.
  • Year by year, Cash from Financing Activities stood at $109180.0 in 2021, then crashed by 139.93% to -$43599.0 in 2022, then skyrocketed by 68984.61% to $30.0 million in 2023, then crashed by 99.87% to $38000.0 in 2024, then plummeted by 60.53% to $15000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for OVID at $15000.0 in Q3 2025, $13000.0 in Q1 2025, and $38000.0 in Q3 2024.